- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Empty Shelves, Urgent Solutions
Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more
Michael Abrams, Managing Partner at Numerof & Associates discusses:
- Pharmacy deserts
- The main factors that are contributing to the closures of both large and independent pharmacies
- Alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities)
- Potential long term consequences if closures continue
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
